Issues with the targeted therapy of non‑small cell lung cancer with thyroid metastases: A case report

Bayram,Ertugrul; Toyran,Tugba; Güney,Burak; Uguz,Aysun Hatice; Gümürdülü,Derya; Paydas,Semra

doi:10.3892/mi.2023.117

November-December 2023 Volume 3 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-December 2023 Volume 3 Issue 6

Full Size Image

Case Report Open Access

Issues with the targeted therapy of non‑small cell lung cancer with thyroid metastases: A case report

Authors:
- Ertugrul Bayram
- Tugba Toyran
- Burak Güney
- Aysun Hatice Uguz
- Derya Gümürdülü
- Semra Paydas
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey, Department of Pathology, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey, Department of Nuclear Medicine, Cukurova University Faculty of Medicine, Sarıçam, Adana 01330, Turkey

Copyright: © Bayram et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 57
|
Published online on: October 17, 2023

https://doi.org/10.3892/mi.2023.117
Expand metrics +

Abstract

Lung cancer is a common malignancy that has usually already metastasized at the time of diagnosis; however, thyroid metastases are extremely rare. Echinoderm microtubule‑associated protein‑like 4‑anaplastic lymphoma kinase (ALK) fusion has been observed in 3‑7% of cases of lung adenocarcinoma. ALK inhibitor therapy has been shown to exert a positive effect on disease progression. The present study describes the case of a patient with ALK‑positive non‑small cell lung carcinoma and thyroid metastases who exhibited a minimal response to ALK inhibitor therapy in the primary lesion, but had a complete pathological response in the thyroid, as confirmed by a thyroid biopsy. The present case report undermines the need for further evidence from genomic testing following this different tumor course in thyroid tissue.

View Figures

View References

1	Brundage MD, Davies D and Mackillop WJ: Prognostic factors in non-small cell lung cancer: A decade of progress. Chest. 122:1037–1057. 2002.PubMed/NCBI View Article : Google Scholar
2	Rudin CM, Brambilla E, Faivre-Finn C and Sage J: Small-cell lung cancer. Nat Rev Dis Primers. 7(3)2021.PubMed/NCBI View Article : Google Scholar
3	Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, Matsuo K and Mitsudomi T: Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer. 77:319–325. 2012.PubMed/NCBI View Article : Google Scholar
4	Aydemirli MD, van Eendenburg JDH, van Wezel T, Oosting J, Corver WE, Kapiteijn E and Morreau H: Targeting EML4-ALK gene fusion variant 3 in thyroid cancer. Endocr Relat Cancer. 28:377–389. 2021.PubMed/NCBI View Article : Google Scholar
5	Kawamoto H, Kaneko Y, Ryu K and Kuwano K: Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement. BMJ Case Rep. 2016(bcr2016217541)2016.PubMed/NCBI View Article : Google Scholar
6	McCusker MG, Russo A, Scilla KA, Mehra R and Rolfo C: How I treat ALK-positive non-small cell lung cancer. ESMO Open. 4 (Suppl 2)(e000524)2019.PubMed/NCBI View Article : Google Scholar
7	Jassem J: Alectinib in crizotinib-resistant, ALK-positive NSCLC. Lancet Oncol. 17:134–135. 2016.PubMed/NCBI View Article : Google Scholar
8	Song Z, Wang M and Zhang A: Alectinib: A novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B. 5:34–37. 2015.PubMed/NCBI View Article : Google Scholar
9	Can AS and Köksal G: Thyroid metastasis from small cell lung carcinoma: A case report and review of the literature. J Med Case Rep. 9(231)2015.PubMed/NCBI View Article : Google Scholar
10	Tang Q and Wang Z: Metastases to the thyroid gland: What can we do? Cancers (Basel). 14(3017)2022.PubMed/NCBI View Article : Google Scholar
11	LaPar DJ, Bhamidipati CM, Lau CL, Jones DR and Kozower BD: The Society of Thoracic Surgeons General Thoracic Surgery Database: Establishing generalizability to national lung cancer resection outcomes. Ann Thorac Surg. 94:216–221; discussion 221. 2012.PubMed/NCBI View Article : Google Scholar
12	Hegerova L, Griebeler ML, Reynolds JP, Henry MR and Gharib H: Metastasis to the thyroid gland: Report of a large series from the Mayo Clinic. Am J Clin Oncol. 38:338–342. 2015.PubMed/NCBI View Article : Google Scholar
13	Antonoff MB and D'Cunha J: Non-small cell lung cancer: The era of targeted therapy. Lung Cancer (Auckl). 3:31–41. 2012.PubMed/NCBI View Article : Google Scholar
14	Dong J, Li B, Lin D, Zhou Q and Huang D: Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front Pharmacol. 10(230)2019.PubMed/NCBI View Article : Google Scholar
15	Chia PL, Mitchell P, Dobrovic A and John T: Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 6:423–432. 2014.PubMed/NCBI View Article : Google Scholar
16	Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, Franklin WA and Varella-Garcia M: Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 16:5581–5590. 2010.PubMed/NCBI View Article : Google Scholar
17	Sgambato A, Casaluce F, Maione P and Gridelli C: Targeted therapies in non-small cell lung cancer: A focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 18:71–80. 2018.PubMed/NCBI View Article : Google Scholar
18	Desai A and Lovly CM: Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: A narrative review. Transl Lung Cancer Res. 12:615–628. 2023.PubMed/NCBI View Article : Google Scholar
19	Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, et al: The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: Is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 149:4141–4148. 2023.PubMed/NCBI View Article : Google Scholar
20	Esagian SM, Grigoriadou GI, Nikas IP, Boikou V, Sadow PM, Won JK and Economopoulos KP: Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: A comprehensive systematic review. J Cancer Res Clin Oncol. 146:2051–2066. 2020.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Issues with the targeted therapy of non‑small cell lung cancer with thyroid metastases: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles